AnaptysBio (ANAB) Stock Price, News & Analysis

Company Overview

AnaptysBio, Inc. is a clinical-stage biotechnology company focused on developing transformative antibody therapeutics in inflammatory and immuno-oncology indications. Founded in 2011 and headquartered in San Diego, California, the company harnesses its proprietary Somatic Hypermutation (SHM) technology platform to generate high-affinity, humanized antibodies with optimized profiles for safety and efficacy. AnaptysBio’s scientific team has deep expertise in antibody engineering, immunology and translational medicine, driving innovative programs from discovery through clinical development.

The company’s pipeline spans multiple therapeutic areas, including immunology and rare diseases. Lead programs include an anti-interleukin-36 receptor antibody for generalized pustular psoriasis, and an anti-Siglec-8 antibody targeting eosinophil and mast cell-mediated disorders. Additional candidates are in development for indications such as chronic spontaneous urticaria, ulcerative colitis and hematologic malignancies. AnaptysBio applies its SHM platform to rapidly screen and optimize novel targets, delivering drug candidates with differentiated mechanisms of action and favorable developability attributes.

AnaptysBio operates research and development facilities in both the United States and Europe, supporting discovery, analytical characterization and early-stage clinical manufacturing. The company has established strategic collaborations, including a multi-target partnership with a leading global pharmaceutical firm to co-develop immuno-oncology antibodies. These alliances provide access to complementary expertise, expand the therapeutic reach of AnaptysBio’s platform and strengthen its clinical development capabilities.

Under the leadership of President and Chief Executive Officer David Hallal, AnaptysBio continues to advance its portfolio through Phase 1 and Phase 2 trials, with key clinical readouts anticipated across its immunology and oncology programs. The management team comprises seasoned drug developers, immunologists and bioprocessing experts committed to translating cutting-edge science into potential new therapies for patients with serious and life-threatening diseases.

Key Stats

• Today's Range: $26.48 to $26.92
• 50-Day Range: $19.45 to $26.95
• 52-Week Range: $12.21 to $41.31
• Volume: 13,181 shs
• Average Volume: 647,007 shs
• Market Capitalization: $779.36 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $42.38
• Consensus Rating: Moderate Buy

AnaptysBio Stock Analysis - MarketRank™

AnaptysBio scored higher than 35% of companies evaluated by MarketBeat, and ranked 758th out of 943 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

AnaptysBio has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 6 buy ratings, 3 hold ratings, and no sell ratings.

Amount of Analyst Coverage

AnaptysBio has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for AnaptysBio are expected to grow in the coming year, from ($6.08) to ($5.36) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of AnaptysBio is -5.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of AnaptysBio is -5.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

AnaptysBio has a P/B Ratio of 11.45. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

35.40% of the float of AnaptysBio has been sold short.

Short Interest Ratio / Days to Cover

AnaptysBio has a short interest ratio ("days to cover") of 14.5, which indicates bearish sentiment.

Change versus previous month

Short interest in AnaptysBio has recently increased by 2.30%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

AnaptysBio does not currently pay a dividend.

Dividend Growth

AnaptysBio does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

35.40% of the float of AnaptysBio has been sold short.

Short Interest Ratio / Days to Cover

AnaptysBio has a short interest ratio ("days to cover") of 14.5, which indicates bearish sentiment.

Change versus previous month

Short interest in AnaptysBio has recently increased by 2.30%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: 1.6 / 5
• News Sentiment: 0.84

News Sentiment

AnaptysBio has a news sentiment score of 0.84. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.96 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for AnaptysBio this week, compared to 5 articles on an average week.

Search Interest

Only 1 people have searched for ANAB on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added AnaptysBio to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, AnaptysBio insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $493,202.00 in company stock.

Percentage Held by Insiders

33.50% of the stock of AnaptysBio is held by insiders. A high percentage of insider ownership can be a sign of company health.

ANAB Stock Analysis - Frequently Asked Questions

How have ANAB shares performed this year?

AnaptysBio's stock was trading at $13.24 on January 1st, 2025. Since then, ANAB stock has increased by 101.5% and is now trading at $26.68.

How were AnaptysBio's earnings last quarter?

AnaptysBio, Inc. (NASDAQ:ANAB) issued its quarterly earnings results on Monday, May, 5th. The biotechnology company reported ($1.28) EPS for the quarter, topping the consensus estimate of ($1.30) by $0.02. The biotechnology company had revenue of $27.77 million for the quarter, compared to the consensus estimate of $15.27 million. AnaptysBio had a negative net margin of 125.70% and a negative trailing twelve-month return on equity of 282.47%.

Is AnaptysBio buying back stock?

AnaptysBio's Board of Directors initiated a share buyback program on Monday, March 24th 2025, which permits the company to repurchase $75,000,000 in outstanding shares, according to EventVestor. This means that the company could reacquire up to 13.1% of its shares through open market purchases. Shares buyback programs are typically an indication that the company's leadership believes its stock is undervalued.

When did AnaptysBio IPO?

AnaptysBio (ANAB) raised $60 million in an initial public offering (IPO) on Thursday, January 26th 2017. The company issued 4,000,000 shares at $14.00-$16.00 per share. Credit Suisse and Stifel acted as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

Who are AnaptysBio's major shareholders?

Top institutional investors of AnaptysBio include Assenagon Asset Management S.A. (0.06%). Insiders that own company stock include Ecor1 Capital, Llc, Daniel Faga, Paul F Lizzul, Eric J Loumeau, Hollings Renton, Dennis Mulroy and Dennis M Fenton.
View institutional ownership trends.

How do I buy shares of AnaptysBio?

Shares of ANAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of AnaptysBio own?

Based on aggregate information from My MarketBeat watchlists, some other companies that AnaptysBio investors own include Meta Platforms (META), NVIDIA (NVDA), Tesla (TSLA), Alibaba Group (BABA), Advanced Micro Devices (AMD), Moderna (MRNA) and Alphabet (GOOG).

Company Calendar

• Last Earnings: 5/05/2025
• Today: 7/18/2025
• Next Earnings (Estimated): 8/04/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ANAB
• CIK: 1370053
• Web: www.anaptysbio.com
• Phone: (858) 362-6295
• Fax: N/A
• Employees: 100
• Year Founded: 2005

Price Target and Rating

• Average Price Target for AnaptysBio: $42.38
• High Price Target: $90.00
• Low Price Target: $20.00
• Potential Upside/Downside: +58.8%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.80
• Research Coverage: 10 Analysts

Profitability

• EPS (Trailing Twelve Months): ($4.85)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$145.23 million
• Net Margins: -125.70%
• Pretax Margin: -125.66%
• Return on Equity: -282.47%
• Return on Assets: -30.79%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 8.25
• Quick Ratio: 8.25

Sales & Book Value

• Annual Sales: $91.28 million
• Price / Sales: 8.59
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.33 per share
• Price / Book: 11.45

Miscellaneous

• Outstanding Shares: 29,380,000
• Free Float: 19,538,000
• Market Cap: $783.86 million
• Optionable: Optionable
• Beta: -0.27